User profiles for P. W. Boros

Piotr W. Boros

National TB & Lung Diseases Research Institute
Verified email at igichp.edu.pl
Cited by 1402

Measurement of FEF25–75% and FEF75% does not contribute to clinical decision making

…, JJ Pretto, DJ Brazzale, PW Boros - European …, 2014 - Eur Respiratory Soc
The aim of this study was to determine the added value of measuring the forced expiratory
flow at 25–75% of forced vital capacity (FVC) (FEF 25–75% ) and flow when 75% of FVC has …

International consensus on lung function testing during the COVID-19 pandemic and beyond

…, S Bayat, N Beydon, PW Boros… - ERJ open …, 2022 - Eur Respiratory Soc
Coronavirus disease 2019 (COVID-19) has negatively affected the delivery of respiratory
diagnostic services across the world due to the potential risk of disease transmission during …

Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry

PH Quanjer, DJ Brazzale, PW Boros… - European Respiratory …, 2013 - Eur Respiratory Soc
The aim of this study was to determine the diagnostic and interpretative consequences of
adopting the Global Lungs Initiative (GLI) 2012 spirometric prediction equations. We assessed …

Grading the severity of airways obstruction: new wine in new bottles

…, JJ Pretto, DJ Brazzale, PW Boros - European Respiratory …, 2014 - Eur Respiratory Soc
The objective of this study was to redesign the current grading of obstructive lung disease
so that it is clinically relevant and free of biases related to age, height, sex and ethnic group. …

[HTML][HTML] Guidelines of the polish respiratory society on the diagnosis and treatment of progressive fibrosing interstitial lung diseases other than idiopathic pulmonary …

…, A Barczyk, B Batko, K Błasińska, PW Boros… - … in Respiratory Medicine, 2022 - mdpi.com
Highlights The working group of the Polish Respiratory Society (PTChP) developed guidelines
for diagnosis and treatment of PF-ILD. What are the main findings? A multidisciplinary …

Impaired lung compliance and DL, CO but no restrictive ventilatory defect in sarcoidosis

PW Boros, PL Enright, PH Quanjer… - European …, 2010 - Eur Respiratory Soc
Sarcoidosis is a systemic granulomatous disease with predominant manifestation in the
lungs, often presenting as interstitial lung disease. Pulmonary function abnormalities in …

Guidelines of the Polish Respiratory Society for diagnosis and treatment of idiopathic pulmonary fibrosis

…, I Bestry, AJ Białas, PW Boros… - Advances in …, 2020 - journals.viamedica.pl
Introduction: This document presents the guidelines of the Polish Respiratory Society (PTChP,
Polskie Towarzystwo Chorób Płuc) for diagnosis and treatment of idiopathic pulmonary …

What comorbidities accompany sarcoidosis? A large cohort (n= 1779) patients analysis.

MM Martusewicz-Boros, PW Boros, E Wiatr… - … Vasculitis, and Diffuse …, 2015 - europepmc.org
Background Sarcoidosis is a systemic granulomatous multiorgan disease with the most common
manifestation is in the chest, although the granulomas can also involve all other organs …

[HTML][HTML] Prevalence of cardiac sarcoidosis in white population: a case–control study: Proposal for a novel risk index based on commonly available tests

MM Martusewicz-Boros, PW Boros, E Wiatr, J Zych… - Medicine, 2016 - journals.lww.com
Cardiac sarcoidosis (CS) is a life-threatening and underdiagnosed manifestation of the
disease, which requires a complicated and expensive diagnostic pathway. There is a need for …

Inhaled therapies in patients with moderate COPD in clinical practice: current thinking

A Ariel, A Altraja, A Belevskiy, PW Boros… - … journal of chronic …, 2017 - Taylor & Francis
COPD is a complex, heterogeneous condition. Even in the early clinical stages, COPD
carries a significant burden, with breathlessness frequently leading to a reduction in exercise …